Drug · CHEMBL6068614
Comparisons in its trials14
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
1 to 14 of 14
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Octaplex vs Frozen Plasma: Comparison of the Incidence of Death Between Octaplex and FP Groups | 7 of 213 | 8 of 207 | 420 | NCT05523297 | Trial comparisons |
| Octaplex vs Frozen Plasma: Comparison of Incidence of Serious Treatment-emergent Adverse Events Between Octaplex and FP Groups | 77 of 213 | 98 of 207 | 420 | NCT05523297 | Trial comparisons |
| Octaplex vs Frozen Plasma: deaths from any cause | 7 of 213 | 8 of 207 | 420 | NCT05523297 | Trial comparisons |
| Octaplex vs Frozen Plasma: serious adverse events | 77 of 213 | 98 of 207 | 420 | NCT05523297 | Trial comparisons |
| Beriplex® P/N vs Fresh Frozen Plasma: serious adverse events | 32 of 103 | 26 of 109 | 212 | NCT00708435 | Trial comparisons |
| Octaplex vs Beriplex P/N (Kcentra): deaths from any cause | 5 of 105 | 1 of 103 | 208 | NCT02740335 | Trial comparisons |
| Octaplex vs Beriplex P/N (Kcentra): serious adverse events | 13 of 105 | 6 of 103 | 208 | NCT02740335 | Trial comparisons |
| Beriplex® P/N vs Fresh Frozen Plasma: 45-Day All-cause Mortality | 9 of 98 | 5 of 104 | 202 | NCT00708435 | Trial comparisons |
| Fresh Frozen Plasma vs Prothrombin Complex Concentrate: deaths from any cause | 2 of 49 | 1 of 51 | 100 | NCT02557672 | Trial comparisons |
| Fresh Frozen Plasma vs Prothrombin Complex Concentrate: serious adverse events | 44 of 49 | 45 of 51 | 100 | NCT02557672 | Trial comparisons |
| Fixed Dose 4FPCC vs Variable Dose 4FPCC: Number of Participants Who Demonstrated Significant Reversal of INR Within 15 Minutes | 21 of 34 | 33 of 37 | 71 | NCT03064035 | Trial comparisons |
| Fixed Dose 4FPCC vs Variable Dose 4FPCC: deaths from any cause | 0 of 34 | 0 of 37 | 71 | NCT03064035 | Trial comparisons |
| Fixed Dose 4FPCC vs Variable Dose 4FPCC: Number of Participants With a Thromboembolic Event | 0 of 34 | 0 of 37 | 71 | NCT03064035 | Trial comparisons |
| Fixed Dose 4FPCC vs Variable Dose 4FPCC: serious adverse events | 0 of 34 | 0 of 37 | 71 | NCT03064035 | Trial comparisons |
pipelines-2026-09-18-0.3.1
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL6068614/comparisons